Phase 1 Malignant Pleural Mesothelioma Clinical Trials
8 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–8 of 8 trials
Recruiting
Phase 1
CT-95 in Advanced Cancers Associated With Mesothelin Expression
Colorectal, CancerMesothelin-Expressing TumorsEpithelial Ovarian Cancer+8 more
Context Therapeutics Inc.70 enrolled9 locationsNCT06756035
Recruiting
Phase 1Phase 2
Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma
Malignant Pleural Mesothelioma
University Hospital, Antwerp15 enrolled3 locationsNCT05765084
Not Yet Recruiting
Phase 1
A Phase 1a/1b Dose-Escalation and Expansion Study of [¹77Lu]Lu-FAP-2286 Radioligand Therapy in Combination with Dual Immune Checkpoint Blockade (Nivolumab and Ipilimumab) in Patients with Unresectable or Advanced Malignant Pleural Mesothelioma (MPM)
Malignant Pleural Mesothelioma
South Metropolitan Health Service50 enrolled2 locationsACTRN12626000505303
Recruiting
Phase 1Phase 2
Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma
Malignant Pleural Mesotheliomas
Beijing Biotech36 enrolled1 locationNCT07510815
Recruiting
Phase 1
A Study of NX-1607 in Adults With Advanced Malignancies
Gastric CancerNon-small Cell Lung Cancer (NSCLC)Cervical Cancer+11 more
Nurix Therapeutics, Inc.345 enrolled17 locationsNCT05107674
Recruiting
Phase 1
APG-2449 in Patients With Advanced Solid Tumors
Esophageal CancerOvarian CancerNon-small Cell Lung Cancer+2 more
Ascentage Pharma Group Inc.165 enrolled9 locationsNCT03917043
Recruiting
Phase 1
The first testing of TargomiRs in the human setting: dose-finding studies in patients with recurrent malignant pleural mesothelioma and non-small cell lung cancer
Malignant Pleural Mesothelioma
Asbestos Disease Research Institute30 enrolled3 locationsACTRN12614001248651
Completed
Phase 1
CD-40 activating antibody (CP-870,893) in combination with cisplatin and pemetrexed in unresectable malignant mesothelioma: a phase Ib study
unresectable malignant pleural mesothelioma
Sir Charles Gairdner Hospital15 enrolled1 locationACTRN12609000294257